Curis (CRIS)
Develops emavusertib combinations for primary central nervous system lymphoma and chronic lymphocytic leukemia.
Something off on this page? Send us feedback.
Develops emavusertib, an oral IRAK4/FLT3 inhibitor, for combination studies in PCNSL and CLL. As a pre-commercial cancer-drug R&D business, development is funded through capital markets, collaborations, and strategic transactions while operations rely on third parties.
Develops emavusertib, an oral IRAK4/FLT3 inhibitor, as its operating priority in combination studies for primary central nervous system lymphoma and chronic lymphocytic leukemia. The single reportable segment is cancer-drug R&D; early development across PCNSL and CLL is supported by a small organization focused on clinical, regulatory, financing, and partnership work.
Operates from the United States while holding worldwide emavusertib rights except India and Russia under its Aurigene license. No products are approved or commercialized, following the sale of the former Erivedge royalty interest, so the model relies on equity and warrant financings, collaborations, strategic transactions, and potential future license or product economics. Clinical operations, manufacturing, and any future commercialization depend on third parties.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $5.6M · Total debt $1.0M · Total assets $19.0M · Shareholders' equity $4.7M
- Revenue
- $0
- Operating income
- −$9.9M
- Net income
- −$8.6M
No dividends on record.
| Institutions42 holders · as of Mar 31, 2026 | 40.45% | 788.3K shares | |
| Insiders6 holders · as of Apr 1, 2026 | 1.02% | 20.0K shares | |
| Otherremainder | 58.53% | 1.14M shares |
1.95M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Bleichroeder LPInstitution | 9.75% | 3.80M | 13Fas of Mar 31, 2026 |
Stonepine Capital Management, LLCInstitution | 9.56% | 3.73M | 13Fas of Mar 31, 2026 |
Nantahala Capital Management, LLCInstitution | 5.13% | 2.00M | 13Fas of Mar 31, 2026 |
Sphera Funds Management Ltd.Institution | 5.12% | 1.99M | 13Fas of Mar 31, 2026 |
Cable Car Capital LLCInstitution | 3.42% | 1.33M | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Mar 31, 2026 | Kenneth I. Kaitin | director | +10,000 | $0.5487 |
- BeOne Medicines (ADR)
Zanubrutinib-based CLL and PCNSL regimens contest the same patients.
- AbbVie
Established ibrutinib and venetoclax alternatives in CLL and PCNSL.
- AstraZeneca (ADR)
IRAK4 and fixed-duration CLL alternatives backed by a global leader.
- Gilead Sciences
Yescarta brings a CAR-T alternative to relapsed/refractory PCNSL.
- Nurix Therapeutics
A brain-penetrant BTK degrader targets CLL and CNS B-cell disease.
- Rigel Pharmaceuticals
R289 is a direct IRAK1/4-pathway rival in hematologic oncology.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Curis | $1.40 | +0.43% | $2.7M | — | — | 0.6 | −57.9% |
| BeOne Medicines (ADR) | $361.00 | −0.21% | $38.66B | 5.0 | 46.1 | 6.7 | +29.6% |
| AbbVie | $261.07 | −0.24% | $462.37B | 73.7 | 17.2 | 7.2 | +10.2% |
| AstraZeneca (ADR) | $163.56 | +1.18% | $250.67B | 24.3 | 15.2 | 4.1 | +6.4% |
| Gilead Sciences | $149.20 | −0.27% | $185.75B | — | 16.5 | 6.1 | +10.2% |
| Nurix Therapeutics | $25.45 | −1.24% | $2.68B | — | — | 72.9 | −79.5% |
| Rigel Pharmaceuticals | $49.45 | +4.11% | $914.4M | 3.0 | 14.7 | 3.3 | −22.6% |
| Median | 14.6 | 16.5 | 6.4 | +8.3% |